Cellectar Biosciences has expanded its licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin with iopofosine I 131 in pediatric cancers, the company announced today.

According to a release, Cellectar has an exclusive license to develop and commercialize iopofosine in various pediatric solid cancers, such as high-grade glioma, neuroblastoma and sarcoma.

“This licensing agreement further strengthens our iopofosine I 131 patent portfolio and our industry-leading position in radiopharmaceutical patent grants and applications,” Cellectar CEO James Caruso said in a statement. “It also expands our long-standing relationships with the University of Wisconsin.”

Financial details of the agreement were not disclosed.